VC-backed Vyome appoints two to board

New Delhi, India-based Vyome Biosciences, a clinical stage dermatology based biopharmaceutical company, has named Dr. Bhaskar Chaudhuri and Alan Rosling to its board of directors. Chaudhuri is an operating partner at Frazier Healthcare Ventures while Rosling is a is senior advisor at Navam Capital. Vyome’s backers included Kalaari Capital, Sabre Partners, Aarin Capital and Navam Capital.


NEW DELHI–(BUSINESS WIRE)–Vyome Biosciences, a clinical stage dermatology based innovative biopharmaceutical company, which is pioneering the development of next generation antibiotics and antifungal agents that target antimicrobial resistance for opportunist pathogens of the skin, announced today the appointment of Dr. Bhaskar Chaudhuri, Ph.D. and Alan Rosling to its Board of Directors.

Dr. Bhaskar Chaudhuri has more than 25 years of experience with leading biopharmaceutical companies in leadership, strategy and management, drug research & development, and commercialization in the US, EU and emerging markets. He has led the development and FDA approval of multiple New Drug Applications (NDAs). Dr. Chaudhuri served as President and CEO of Dow Pharmaceuticals for seven years, leading up to their acquisition by Valeant Pharmaceuticals. After acquisition, Dr. Chaudhuri served as the President of Valeant Pharmaceuticals International from January 2009 till September 2010. He is currently an Operating Partner of Frazier Healthcare Ventures. Dr. Chaudhuri has a Doctorate in Physical Pharmacy.

“As Vyome scales up multiple drug development programs, enters clinical trials and accelerates the commercialization phase, Dr. Chaudhuri will add tremendous strategic experience to the Board. His vast experience in commercializing novel dermatology drugs, and leadership with top-tier pharmaceutical companies will brings significant value to Vyome”, said Venkateswarlu Nelabhotla, Co-founder & CEO of Vyome Biosciences.

“Vyome is a proving to be a highly credible innovative player in the life sciences industry, with novel platforms and drug development programs, and I am delighted to be a part of the Company’s illustrious Board of Directors. Vyome’s current portfolio of innovative and breakthrough products provides a strong foundation for the company to emerge as a global leader in its field,” Dr. Chaudhuri added.

Alan Rosling is Senior Advisor at Navam Capital. Alan co-Founded Kiran Energy in 2010. Prior to co-founding Kiran, Alan was Executive Director of Tata Sons Limited, and Chairman of the Jardine Matheson Group in India. Earlier in his career Alan served as Special Advisor to British Prime Minister John Major and also worked in investment banking at S.G. Warburg & Co. in London. Alan graduated with an MBA from Harvard Business School as a Baker Scholar and holds an MA from Cambridge University. He was awarded the Order of the British Empire (OBE) in 1994 and the Commander of the Order of the British Empire (CBE) in 2014.

“I am delighted that Dr. Chaudhuri is getting involved with Vyome at this crucial stage of commercialization– he has a stellar reputation as a business strategist, and his extensive experience in the biopharmaceuticals industry will be a valuable asset for the Company. Alan Rosling brings strong global business experience to the Board, and he will be a tremendous resource for the company as it continues to go from strength to strength in the coming years,” commented Dr. Raghunath Mashelkar, Padma Vibhushan recipient and the Chairman of Vyome’s Board of Directors.

About Vyome Biosciences Private Limited

Vyome Biosciences ( is a clinical stage dermatology based biopharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant Acne, other opportunistic pathogens and antifungal agents. Vyome has put-together a team of scientific and management experts from India and USA to deliver company’s growth plans. Vyome is co-promoted by Shiladitya Sengupta, Venkateswarlu Nelabhotla, Rajesh Gokhale and Rajeev Mantri and it is currently backed by leading venture capital and private equity funds, including Kalaari Capital, Sabre Partners, Aarin Capital and Navam Capital.